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OBJECTIVES The purpose of this study was to investigate the susceptibility of estrogen-induced small low
density lipoprotein (LDL) particles to oxidation.
BACKGROUND Estrogen replacement therapy in postmenopausal women has an antioxidant effect that
opposes oxidation of LDL particles. Estrogen-induced increases in plasma triglyceride
concentrations, however, decrease LDL particle size, which may act counter to this
antioxidant effect. It has not been evaluated whether estrogen-induced small LDL particles
are atherogenic.
METHODS In 24 lean and healthy postmenopausal women treated with conjugated equine estrogen
(0.625 mg daily) for three months, plasma lipid concentrations and diameter of LDL particles
were measured before and after therapy. Susceptibility of LDL to oxidation was determined
by measuring the concentration of thiobarbituric acid-reactive substances (TBARS) after
incubation with CuSO4.
RESULTS Estrogen significantly decreased plasma concentrations of total cholesterol, LDL-cholesterol
and apolipoprotein B, while increasing concentrations of triglyceride, high-density lipopro-
tein cholesterol and apolipoprotein A-I. Estrogen-induced changes in LDL particle diameter
correlated negatively with changes in plasma triglyceride concentrations (r 5 20.55, p ,
0.005) and with changes in concentrations of LDL-derived TBARS (r 5 20.49, p , 0.005).
In subjects with substantial estrogen-induced plasma triglyceride increases, estrogen signifi-
cantly reduced the diameter of LDL particles (p , 0.05) and significantly increased the
concentration of LDL-derived TBARS (p , 0.05). In contrast, estrogen significantly reduced
the concentration of LDL-derived TBARS (p , 0.05) and caused no significant change in
LDL particle diameter in subjects whose plasma triglyceride concentration was unchanged
with estrogen therapy.
CONCLUSIONS Because estrogen-induced plasma triglyceride increases may produce small LDL particles that
are more susceptible to oxidation, antioxidant effects of estrogen might be offset in patients
showing such a triglyceride increase. (J Am Coll Cardiol 2001;37:425–30) © 2001 by the
American College of Cardiology
Low density lipoprotein (LDL), a major cholesterol-
carrying plasma lipoprotein, has been implicated in the
formation of atherosclerotic lesions (1). Plasma concentra-
tions of LDL-cholesterol increase after menopause (2),
rendering women more susceptible to coronary heart disease
(CHD) with increasing age (3). We demonstrated previ-
ously that in postmenopausal and oophorectomized women,
a decrease in the plasma concentration of estrogen leads to
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enhanced activity of lipoprotein lipase, which may increase
the plasma LDL concentrations (4). Additionally, Arca et
al. (5) have suggested that hypercholesterolemia in post-
menopausal women results from impairment of the LDL
receptor.
Low density lipoproteins are heterogeneous in size and
density (6), and not all LDL subfractions are equally
atherogenic. Smaller, denser LDL particles are associated
with an increased risk of CHD (7). We previously demon-
strated that the size of LDL particles decreased after
menopause, whether natural or surgically induced (8). Thus,
an increased plasma LDL concentration associated with a
reduced size of LDL particles may be atherogenic in women
with low plasma concentrations of estrogen.
Estrogen replacement therapy (ERT) in postmenopausal
women exerts favorable effects on lipid metabolism by
reducing the plasma concentrations of LDL particles and
increasing those of high density lipoprotein (HDL) particles
(9). Epidemiologic studies indicated that postmenopausal
ERT significantly reduced mortality from CHD and other
cardiovascular disease (10–12). In contrast, the Heart and
Estrogen/progestin Replacement Study (HERS) demon-
strated that estrogen and progestin therapy did not reduce
the overall rate of coronary events in postmenopausal
women with established coronary disease (13). We previ-
ously reported that estrogen-induced increases in plasma
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triglyceride concentration can reduce the size of LDL
particles (14,15). The resulting small LDL particles are
more susceptible than larger ones to oxidative modification
(16), which is considered one of the initial steps in the
development of atherosclerosis. As a result, the beneficial
effects of estrogen could be partially offset by a concomitant
decrease in LDL particle size.
In this study, we investigated whether estrogen-induced
small LDL particles are atherogenic by measuring the size
of LDL particles and the susceptibility of LDL to oxidative
modification in postmenopausal women treated with estro-
gen.
METHODS
Subjects. We studied 24 naturally postmenopausal Japa-
nese women who satisfied the following conditions during
this period: mean age, 53 years; range, 45 to 62 years; mean
body mass index, 21.5 g/m2; range, 17.7 to 27.0 g/m2; mean
menopausal period, 4.3 years; range, 1.5 to 10.0 years).
These patients had not undergone ovariectomy. None of the
subjects had menstruated for at least one year. None of them
smoked, used caffeine or alcohol, had a history of hyperten-
sion, thyroid disease, liver disease, diabetes mellitus or
cardiovascular disease, and none was currently taking any
medication known to influence lipoprotein metabolism.
None of the women was taking ERT before this study. No
subject underwent exercise or dietary therapy during the
study period. Written informed consent was obtained from
each subject before admission to the study. The study design
was approved by the ethics committee of Kochi Medical
School.
Study design. Each subject received oral conjugated equine
estrogen 0.625 mg daily for three months. Endometrial
biopsy specimens and blood samples were obtained before
and after treatment. Venous blood samples were drawn into
tubes containing 1 mg/mL ethylenediaminetetra-acetic acid
(EDTA) between 8:00 AM and 10:00 AM after a 12-h fast.
Samples were centrifuged immediately at 1,500 3 g for
20 min at 4°C to obtain plasma. Compliance with estrogen
therapy was assessed from plasma concentrations of estrone
(E1) and estradiol (E2) measured by radioimmunoassay
(17) before and after therapy.
Measurement of lipids and isolation of LDL. Plasma
concentrations of total cholesterol and triglyceride were
measured by enzymatic methods as previously described
(18). The concentration of HDL-cholesterol was deter-
mined by similar methods after apolipoprotein
B-containing lipoproteins had been precipitated with so-
dium phosphotungstate in the presence of magnesium
chloride (19). Plasma concentrations of apolipoprotein A-I,
A-II and B were measured by a turbidimetric immunoassay
(19). Low-density lipoprotein (density, 1.019 to 1.063) were
fractionated from freshly drawn (,24 h) plasma samples by
ultracentrifugation according to the method of Havel et al.
(20). Concentrations of LDL-cholesterol were assayed en-
zymatically (18).
LDL particle diameter. Low density lipoprotein was sub-
jected to gradient gel electrophoresis using 2% to 15%
nondenaturing polyacrylamide-agarose gels. The apparatus
was filled with a buffer consisting of 0.025 mol/L Tris,
0.192 mol/L glycine and 0.1% sodium dodecyl sulfate at a
pH of 8.4. After a 2-h preelectrophoresis at 200 volts, 5 mL
aliquots of the LDL fraction (5 to 10 mg protein) were
applied to the gel. A reference protein mixture (Molecular
Weight Marker, Daiichi, Tokyo, Japan) and carboxylated
latex beads (Duke Science, Palo Alto, California) were used
as standards for molecule size and mass. Electrophoresis was
performed at 4°C for 26 h as follows: 2 h at 30 volts, 12 h
at 50 volts and 12 h at 150 volts (21,22). The gels were then
fixed in 40% acetic acid for 1 h, stained for 45 min in 0.1%
Coomassie G-250 (Nacalai, Kyoto, Japan) prepared in 10%
acetic acid and 30% ethanol and then destained in a mixture
of 7.5% acetic acid and 10% ethanol. The gels were
subjected to a gentle horizontal rotation during the fixing,
staining and destaining. The distribution profile of the LDL
subfractions was determined by densitometric scanning of
gels at 633 nm (Shimadzu, Kyoto, Japan). The apparent
diameter of the major LDL subfractions was determined by
comparing the results with a calibration curve constructed
using ferritin (12.20 nm), thyroglobulin (17.00 nm) and
latex beads (38.00 nm) as reference samples (22).
Susceptibility of LDL to oxidation. To remove EDTA,
the isolated LDL fraction was dialyzed in darkness at 4°C
for 48 h against 30 mM sodium phosphate buffer containing
150 mM NaCl, which was made oxygen-free by vacuum
degassing followed by purging with nitrogen. The buffer
was changed after 24 h of dialysis. The EDTA-free dialyzed
LDL subfraction (200 mg/mL) was oxidized by incubating
at 37°C for 3 h after the addition of 5 mM CuSO4.
Concentrations of thiobarbituric acid-reactive substances
(TBARS) in the LDL fraction were determined according
to the method of Ohkawa et al. (23). In brief, 1.5 mL of
20% acetic acid (pH 3.5) and 1.5 mL of a 0.8% TBA
solution were added to the LDL solution, and the volume
was brought to 4.0 mL with distilled water. The mixture
was shaken thoroughly and heated in an oil bath at 95°C for
60 min. After the mixture was cooled with tap water,
1.0 mL of distilled water and 5.0 mL of butyl alcohol
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containing pyridine (15:1, v/v) were added, and the sample
was shaken gently for 5 min. After centrifugation at
1,500 3 g for 10 min, the butyl alcohol-pyridine phase
containing the TBARS was separated, and absorbance was
measured in this phase at 532 nm. The results are expressed
as molar equivalents malondialdehyde per milligrams of
protein using malondialdehyde derived from tetrame-
thoxypropane as a standard and double-distilled water as a
control.
Statistical analysis. Data are expressed as the mean 6
standard deviation. Changes in lipid concentrations and
diameters of LDL particles were analyzed by a paired t test.
Regression lines were determined by the least squares
method. Differences in the population of LDL subclass
patterns were determined by McNemar’s test. A level of p ,
0.05 was accepted as statistically significant.
RESULTS
Histological analysis of the endometrial biopsy specimens
showed no hyperplasia before or after treatment. Estrogen
treatment significantly increased the plasma concentrations
of E1 (47.2 6 30.8 pg/mL to 182.2 6 28.5 pg/mL, p ,
0.001) and those of E2 (14.9 6 6.1 pg/mL to 56.9 6
26.6 pg/mL, p , 0.001). Estrogen therapy significantly
reduced plasma concentrations of total cholesterol, LDL-
cholesterol and apolipoprotein B and significantly increased
plasma concentrations of HDL-cholesterol, triglyceride and
apolipoprotein A-I (Table 1). The diameter of LDL parti-
cles was significantly reduced by estrogen treatment. Estro-
gen changed the LDL subclass pattern significantly from A
to B in six subjects. Overall, concentrations of TBARS
derived from LDL after reaction with CuSO4 did not
change significantly by estrogen treatment (Table 2). Low-
density lipoprotein diameter was correlated negatively with
plasma level of triglyceride (pretreatment: r 5 20.91, p ,
0.001; posttreatment: r 5 20.86, p , 0.001) (Fig. 1A) and
with the concentration of LDL-derived TBARS (pretreat-
ment: r 5 20.70, p , 0.001; posttreatment: r 5 20.64,
p , 0.001) (Fig. 2A). Estrogen-induced changes in LDL
particle diameter showed a negative correlation with
changes in the plasma triglyceride concentrations (r 5
20.55, p , 0.005) (Fig. 1B) and with changes in the
concentration of LDL-derived TBARS (r 5 20.49, p ,
0.005) (Fig. 2B). Estrogen-induced changes in plasma
triglyceride concentrations showed a significant positive corre-
lation with changes in the concentration of LDL-derived
TBARS (r 5 0.66, p , 0.001) (Fig. 3). According to the
regression equation, the greatest estrogen-induced plasma
Figure 1. (A) Relationship between plasma triglyceride concentrations and
LDL diameter. Open circles and solid line indicate pretreatment. Closed
circles and dashed line indicate posttreatment. Pretreatment: y 5
20.014x 1 27.47, r 5 20.91, p , 0.001; posttreatment: y 5 20.012x 1
26.94, r 5 20.86, p , 0.001. (B) Relationship between estrogen-induced
changes in plasma triglyceride concentrations and changes in LDL diam-
eter (y 5 20.011x 2 0.33, r 5 20.55, p , 0.005). LDL 5 low density
lipoprotein.
Figure 2. (A) Relationship between LDL diameter and the concentration
of LDL-derived TBARS. Open circles and solid line indicate pretreat-
ment. Closed circles and dashed line indicate posttreatment. Pretreat-
ment: y 5 26.22x 1 180.63, r 5 20.70, p , 0.001; posttreatment: y 5
27.97x 1 222.43, r 5 20.64, p , 0.001. (B) Relationship between
estrogen-induced changes in LDL diameter and changes in the concen-
tration of LDL-derived TBARS (y 5 24.97x 21.99, r 5 20.49, p ,
0.005). LDL 5 low density lipoprotein; TBARS 5 thiobarbituric acid-
reactive substances.
Table 1. Changes in Plasma Lipids and Lipoproteins
Pretreatment Posttreatment p Value
Total cholesterol
(mg/dL)
240.24 6 45.12 219.14 6 30.54 0.0016
Triglyceride (mg/dL) 116.13 6 72.09 135.25 6 69.75 0.0107
HDL-cholesterol
(mg/dL)
62.52 6 12.38 65.0 6 13.58 0.0399
LDL-cholesterol
(mg/dL)
157.54 6 46.14 129.59 6 29.92 0.0001
Apolipoprotein A-I
(mg/dL)
153.10 6 20.87 162.75 6 24.61 0.0401
Apolipoprotein A-II
(mg/dL)
37.51 6 5.29 39.43 6 6.87 0.2183
Apolipoprotein B
(mg/dL)
114.53 6 30.47 104.97 6 24.89 0.0028
HDL 5 high-density lipoprotein; LDL 5 low density lipoprotein.
Table 2. Changes in the Concentration of LDL-derived
TBARS, Diameter of LDL Particles and the Prevalence of
LDL Subclass Patterns
Pretreatment Posttreatment p Value
LDL-derived TBARS
(nM/200 mg)
20.11 6 10.00 20.52 6 24.89 0.7494
LDL-diameter (nm) 25.80 6 1.12 25.32 6 0.97 0.0008
LDL subclass pattern
A/B (no. of subjects)
16/8 10/14 0.0412
LDL subclass pattern A, LDL particle diameter at least 25.5 nm; LDL subclass
pattern B, LDL particle diameter less than 25.5 nm.
LDL 5 low-density lipoprotein; TBARS 5 thiobarbituric acid-reactive substances.
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triglyceride increase not associated with an increase in LDL-
derived TBARS was 15 mg/dL (Fig. 3). Accordingly, subjects
were divided into two groups with estrogen-induced plasma
triglyceride increases either greater or less than 15 mg/dL.
In subjects whose plasma triglyceride increase was less
than 15 mg/dL, estrogen significantly increased the plasma
concentrations of HDL-cholesterol and apolipoprotein A-I.
In contrast, concentrations of HDL-cholesterol and apoli-
poprotein A-I were not altered in subjects whose plasma
triglyceride increased more than 15 mg/dL. Plasma concen-
trations of total cholesterol, LDL-cholesterol and apoli-
poprotein B were significantly reduced by estrogen treat-
ment in both groups (Table 3). In subjects whose plasma
triglyceride concentration increased less than 15 mg/dL,
estrogen treatment significantly reduced the concentration
of LDL-derived TBARS, but LDL particle diameter and
prevalence of LDL subclass patterns did not change signif-
icantly. In contrast, estrogen significantly increased the
concentration of LDL-derived TBARS, significantly re-
duced LDL particle diameter and tended to increase the
prevalence of subclass pattern B among subjects whose
plasma triglyceride increase was at least 15 mg/dL (Table 4).
DISCUSSION
Effects of estrogen on lipids and LDL particle size.
Estrogen lowers plasma concentrations of LDL particles by
stimulating hepatic synthesis of LDL receptors while in-
creasing plasma concentrations of HDL particles via inhi-
bition of hepatic triglyceride lipase activity (9). Consistent
with these findings, this study demonstrated that the con-
centrations of LDL-cholesterol and of apolipoprotein B, a
major apolipoprotein in LDL particles, decreased with
estrogen therapy, while concentrations of HDL-cholesterol
and apolipoprotein A-I, a major apolipoprotein in HDL
particles, increased. Although estrogen has favorable effects
on lipoprotein metabolism, it increases plasma triglyceride
concentrations. Hypertriglyceridemia is also a risk factor for
CHD (24). In this study, estrogen therapy increased the
plasma concentration of triglyceride and reduced the size of
LDL particles. Estrogen-induced changes in plasma triglyc-
eride correlated negatively with the size of LDL particles.
These observations suggest that a plasma triglyceride in-
crease may reduce the size of LDL particles, consistent with
our previous findings (14,15). Accordingly, the small size of
LDL particles in women with low plasma estrogen levels
could be decreased further by estrogen therapy. We previ-
ously outlined the mechanism of the estrogen-induced
decrease in LDL particle size as follows: estrogen-induced
hypertriglyceridemia enhances lipid transfer reactions, re-
sulting in triglyceride-rich and cholesterol ester-poor LDL
particles (25); subsequent hydrolysis of the enriched triglyc-
eride content by lipolytic enzymes may increase the forma-
tion of LDL particles that are smaller than normal.
Two distinct LDL subclass patterns have been identified:
pattern A consists of LDL particles with a diameter of at
least 25.5 nm, and pattern B consists of LDL particles with
a diameter of less than 25.5 nm (26). Pattern B is associated
with an increased incidence of CHD. Campos et al. (27)
have shown that ERT decreased the proportion of large
LDL and increased the proportion of small LDL, conclud-
ing that this adverse effect of estrogen is minimized by the
beneficial effect of estrogen on total, LDL and HDL-
cholesterol levels. In this study, however, estrogen treatment
changed the LDL subclass pattern from A to B in 25% of
subjects, indicating that an estrogen-induced increase in
triglyceride may be atherogenic.
Figure 3. Relationship between estrogen-induced changes in plasma tri-
glyceride concentration and changes in the concentration of LDL-derived
TBARS (y 5 0.11x 21.66, r 5 0.66, p , 0.001). LDL 5 low density
lipoprotein; TBARS 5 thiobarbituric acid-reactive substances.
Table 3. Changes in Plasma Lipids and Lipoproteins According to Triglyceride Increase
Triglyceride Increase <15 mg/dL (n 5 13) Triglyceride Increase >15 mg/dL (n 5 11)
Pretreatment Posttreatment p Value Pretreatment Posttreatment p Value
Total cholesterol (mg/dL) 242.55 6 49.90 217.50 6 35.11 0.0151 237.07 6 40.71 220.11 6 26.96 0.0092
Triglyceride (mg/dL) 137.71 6 86.08 131.00 6 78.58 0.1756 99.20 6 54.03 141.20 6 58.70 0.0001
HDL-cholesterol (mg/dL) 65.55 6 14.42 70.91 6 12.46 0.0388 58.38 6 11.02 61.02 6 13.61 0.3685
LDL-cholesterol (mg/dL) 156.33 6 53.52 129.03 6 33.09 0.013 159.22 6 37.10 130.43 6 26.62 0.0025
Apolipoprotein A-I (mg/dL) 154.00 6 25.91 167.36 6 25.1 0.0484 151.86 6 12.57 158.37 6 25.55 0.3592
Apolipoprotein A-II (mg/dL) 35.73 6 4.05 38.10 6 7.00 0.4278 39.96 6 6.06 41.83 6 5.74 0.3734
Apolipoprotein B (mg/dL) 106.18 6 30.32 95.55 6 25.01 0.0256 126.01 6 28.68 111.80 6 22.42 0.0052
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
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Effects of estrogen on susceptibility of LDL to oxidation.
Plasma LDL particles infiltrate the intimal space of arteries
and are oxidized by oxygen free radicals. Oxidized LDL
particles are readily taken up by macrophages via scavenger
receptors that are not downregulated. These macrophages
accumulate large amounts of cholesterol and develop into
foam cells (28). Therefore, oxidative modification of LDL
plays a key role in the development of atherosclerosis.
Biologic oxidative modification can be mimicked easily by
incubation in cell-free buffer containing copper ions (29). In
this study, LDL peroxidation induced by incubating LDL
with CuSO4 was measured as TBARS, which indicate the
susceptibility of LDL to oxidation. Thiobarbituric acid-
reactive substances did not show overall changes with
estrogen therapy, which indicates that, generally, estrogen
did not protect LDL against oxidative modification. Yet
some in vitro studies have shown estrogen to act as an
antioxidant that inhibits the oxidation of LDL (30,31).
Some clinical studies have also shown that estrogen treat-
ment inhibited the susceptibility of LDL to oxidative
modification (9,32), while another study found that oxida-
tion of LDL particles was not influenced by estrogen (33).
However, estrogen-induced changes in LDL particle diam-
eter correlated negatively with changes in the concentration
of LDL derived TBARS in this study, indicating that an
estrogen-induced decrease in the size of LDL particles
increases the susceptibility of LDL to oxidation. A positive
correlation was observed between estrogen-induced changes
in plasma triglyceride concentrations and changes in the
concentration of LDL-derived TBARS. Thus, estrogen-
induced hypertriglyceridemia may produce small LDL par-
ticles that show increased susceptibility to oxidative modi-
fication.
Relationship between estrogen-induced changes in
plasma triglyceride and lipids, LDL particle size and
LDL oxidation. The regression equation between changes
in plasma triglyceride concentration and changes in the
concentration of LDL-derived TBARS indicated that sub-
jects with increased concentrations of LDL-derived
TBARS had plasma triglyceride elevations greater than
15 mg/dL, and this value was used to divide subjects into
two groups with greater or smaller plasma triglyceride
increases. Plasma HDL-cholesterol and apolipoprotein A-I
concentrations were not changed by estrogen therapy in
patients whose plasma triglyceride concentrations increased
beyond cutoff values, while those parameters were elevated
in patients whose plasma triglyceride concentrations did not
increase. The plasma HDL-cholesterol concentration has
been reported to be inversely associated with plasma triglyc-
eride concentrations; a low plasma HDL-cholesterol con-
centration in patients with hypertriglyceridemia could result
from increased lipid transfer reactions via cholesterol ester
transfer protein (34). Thus, an estrogen-induced increase in
plasma triglyceride may reduce the amount of HDL-
cholesterol in plasma, which was increased by estrogen.
Estrogen decreased plasma concentrations of total cho-
lesterol, LDL-cholesterol and apolipoprotein B in both of
our triglyceride-defined groups. However, the size of LDL
particles was reduced, and the LDL peroxidation was
enhanced by estrogen therapy in the group whose plasma
triglyceride concentrations increased. Small, dense LDL
particles are considered to be easily oxidized because these
particles contain low concentrations of antioxidants and
high concentrations of polyunsaturated fatty acids (35). Our
findings indicate that antioxidative effects of estrogen can be
offset by hypertriglyceridemia-induced small LDL particles
that render the particles more susceptible to oxidative modifi-
cation. In contrast, the size of LDL particles did not change,
and LDL peroxidation was reduced after estrogen therapy in
our group of patients whose plasma triglyceride concentrations
were unchanged. In this group, a stable size of LDL particles
preserved the antioxidative effect of estrogen.
Study limitations. We investigated lean and healthy post-
menopausal women. Obese women with hypertriglyceride-
mia or women with CHD might respond differently. A
reduction in the plasma level of triglyceride might be needed
before ERT in the subjects with hypertriglyceridemia.
Further studies are required to clarify these issues. Since our
subject number was relatively small, the 15 mg/dL plasma
triglyceride increase that served as the cutoff in this study
might not apply in large patient populations.
Conclusions. According to the findings of HERS, estro-
gen and progestin therapy had beneficial effects on plasma
concentrations of LDL-cholesterol and HDL-cholesterol,
but the plasma triglyceride concentration was increased
(13), as in our results. If sufficiently large, this estrogen-
induced increase in plasma triglyceride can be atherogenic
via a decrease in LDL particle size and partially offset the
beneficial effects of estrogen. Studies are needed to investi-
gate whether or not a reduction in plasma triglyceride
concentrations during hormone replacement therapy can
Table 4. Changes in the Concentration of LDL-derived TBARS, Diameter of LDL Particles and the Prevalence of LDL Subclass
Patterns According to Triglyceride Increase
Triglyceride Increase <15 mg/dL (n 5 13) Triglyceride Increase >15 mg/dL (n 5 11)
Pretreatment Posttreatment p Value Pretreatment Posttreatment p Value
LDL-derived TBARS (nM/200 mg) 19.53 6 9.70 16.65 6 10.37 0.0359 21.29 6 19.00 25.54 6 12.32 0.0234
LDL-diameter (nm) 25.60 6 1.27 25.27 6 1.12 0.1172 26.04 6 0.92 25.44 6 0.83 0.0161
LDL-subclass pattern A/B (no. of subjects) 8/5 7/6 0.7728 8/3 3/8 0.0736
LDL subclass pattern A, LDL particle diameter at least 25.5 nm; LDL subclass pattern B, LDL particle diameter less than 25.5 nm.
LDL 5 low density lipoprotein; TBARS 5 thiobarbituric acid-reactive substances.
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reduce the risk of cardiac events in postmenopausal women
with established coronary disease.
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